review papers summarise the design rationale without publishing the full sequence (PMID 39515565)
Eligibility is selective, with strict BMI, age, comorbidity, and previous-treatment criteria, and some participants receive placebo (a dummy version of the drug)
While clinical evidence is still emerging, GLP-1s potential dual ability to reduce the risk of comorbidities and stabilize patients with fewer additional drugs positions them as a cornerstone of modern diabetes care
Studies lasting up to 52 weeks with various GLP-1 medications show no systematic changes in calcitonin concentrations
When retrieving the vial for use, inspect the solution visually before each withdrawalany cloudiness, precipitation, or color change indicates degradation and the solution should be discarded immediately
These expanded studies will test the medication in larger and more diverse populations, assess longer-term outcomes, and provide the data required for regulatory approval submissions to both the FDA and Health Canada